The CCDC71L Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the human CCDC71L gene within the A2780 ovarian adenocarcinoma cell line. This polyclonal knockout model is generated through CRISPR/Cas9-mediated gene disruption, creating a heterogeneous pool of cells with targeted genomic modifications. The polyclonal format maintains population diversity, enabling robust phenotypic screening without clonal selection artifacts.
The A2780 cell line is a human ovarian adenocarcinoma epithelial model isolated from an untreated patient. These cells are tumorigenic and widely employed in ovarian cancer research, particularly in studies examining drug resistance mechanisms and chemotherapeutic sensitivity. The epithelial origin and genetic profile of A2780 provide a clinically relevant context for exploring gene function in high-grade serous ovarian carcinoma.
CCDC71L encodes a coiled-coil domain-containing protein with an uncharacterized function. Coiled-coil domains typically facilitate protein-protein interactions, suggesting that CCDC71L may participate in multiprotein complex assembly or signaling cascades. Currently, no upstream regulators, downstream targets, or interacting partners have been identified for CCDC71L. This knockout tool therefore offers a valuable opportunity to dissect its molecular roles through loss-of-function studies, potentially unveiling novel regulatory networks in ovarian cancer cells.
In the context of ovarian adenocarcinoma, the CCDC71L knockout A2780 polyclonal cells enable the exploration of this gene’s impact on cancer-relevant phenotypes. Researchers can compare knockout and wild-type populations to assess alterations in cell proliferation, apoptotic responses, migratory capacity, or sensitivity to chemotherapeutic agents such as cisplatin. These investigations may uncover contributions of CCDC71L to tumor maintenance, metastasis, or acquired drug resistance, areas of critical importance in ovarian cancer management.
This product supports a wide range of functional genomics applications. Genotypic validation can be performed using Sanger sequencing, while transcript and protein levels are assessed by RT-qPCR and western blotting, respectively. Functional assays may include cell proliferation assays to measure growth kinetics and drug sensitivity assays to evaluate responses to standard-of-care or targeted therapies. The polyclonal population is particularly suited for pooled screening approaches that interrogate phenotypic heterogeneity. For additional information or custom project inquiries, please contact Ascent Research.
